What is CRDL's current stock price?

CRDL (Cardiol Therapeutics Inc.) is currently trading at $1.32 with a market cap of $147.1M.

What sector is Cardiol Therapeutics Inc. in?

Cardiol Therapeutics Inc. (CRDL) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.

Is CRDL a good stock to buy?

Analysts have a Buy consensus on CRDL with a price target of $8.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

CRDL Cardiol Therapeutics Inc.

Healthcare

$1.31+0.00%OpenMarket Cap: $147.1M

As of 2026-05-26

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

8.33

P/S

0.00

EV/EBITDA

-5.09

DCF Value

$0.18

FCF Yield

-11.7%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-229.2%

ROA

-115.7%

ROIC

-146.4%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-10.8M	$—
Q4 null	$0.00	$-7.2M	$—
FY null	$0.00	$-33.8M	$—
Q3 null	$0.00	$-10.0M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$8.00

Target (Median)

$8.00

Target Range

$8.00 - $8.00

2 Strong Buy3 Buy0 Hold0 Sell0 Strong Sell

Canaccord GenuityBuy

2026-04-06

HC Wainwright & Co.Buy

2026-02-10

HC Wainwright & Co.Buy

2025-12-01

Company Info

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Country

Exchange

—

Beta

0.86

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.

Peers

IMA